Literature DB >> 2050175

The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection.

W Krause1, T Mager, G Kühne, T Duka, B Voet.   

Abstract

The plasma concentration of lisuride and prolactin have been measured in twelve healthy male volunteers after IV, IM or SC injection of 25 micrograms lisuride hydrogen maleate as an aqueous solution. After IV administration the plasma lisuride fell in two phases with half-lives of 14 min and 1.5 h. Total clearance was 13 ml.min-1.kg-1. After IM and SC injection the plasma concentrations peaked at 12 to 15 min and the profiles were similar to that found after IV administration. The systemic availabilities were 90% and 94%, respectively. Prolactin concentrations were reduced by a maximum of 60% relative to the normal circadian rhythm after all three routes of administration. The treatments were well tolerated, the only adverse reactions reported by some of the volunteers being mild, transient dizziness, tiredness, and nausea.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050175     DOI: 10.1007/bf00265851

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Direct binding of 3H-lisuride to adrenergic and serotonergic receptors.

Authors:  G Battaglia; M Titeler
Journal:  Life Sci       Date:  1981-08-31       Impact factor: 5.037

2.  Response of central monoaminergic neurons to lisuride: comparison with LSD.

Authors:  M A Rogawski; G K Aghajanian
Journal:  Life Sci       Date:  1979-04-02       Impact factor: 5.037

3.  Effects of dopamine infusion on pituitary hormone secretion in humans.

Authors:  H Leblanc; G C Lachelin; S Abu-Fadil; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

4.  The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man.

Authors:  M Hümpel; W Krause; G A Hoyer; H Wendt; G Pommerenke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

5.  Migraine prophylaxis with Lisuride hydrogen maleate--a double blind study of Lisuride versus placebo.

Authors:  B W Somerville; W M Herrmann
Journal:  Headache       Date:  1978-05       Impact factor: 5.887

6.  Circadian variation of thyrotrophin, determined by ultrasensitive immunoradiometric assay, and the effect of low dose nocturnal dopamine infusion.

Authors:  D J Kerr; V K Singh; M G McConway; G H Beastall; J M Connell; W D Alexander; D L Davies
Journal:  Clin Sci (Lond)       Date:  1987-06       Impact factor: 6.124

7.  Lisuride in the treatment of parkinsonism.

Authors:  R J McDonald; R Horowski
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

8.  Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders.

Authors:  H G Bohnet; J P Hanker; R Horowski; E J Wickings; H P Schneider
Journal:  Acta Endocrinol (Copenh)       Date:  1979-09

9.  Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.

Authors:  G Verde; P G Chiodini; A Liuzzi; R Cozzi; F Favales; L Botalla; B Spelta; D Dalla Bonzana; E Rainer; R Horowski
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

10.  Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effect on plasma prolactin level.

Authors:  M Hümpel; B Nieuweboer; S H Hasan; H Wendt
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  1 in total

1.  A Combined In Vitro/In Silico Approach to Identifying Off-Target Receptor Toxicity.

Authors:  Joseph Leedale; Kieran J Sharkey; Helen E Colley; Áine M Norton; David Peeney; Chantelle L Mason; Jean G Sathish; Craig Murdoch; Parveen Sharma; Steven D Webb
Journal:  iScience       Date:  2018-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.